This phase I/II trial studies the side effects and best dose of nanoparticle albumin-bound
rapamycin and how well it works when given together with pazopanib hydrochloride in treating
participants with nonadipocytic soft tissue sarcomas that has spread to other places in the
body (advanced). Nanoparticle albumin-bound rapamycin and pazopanib hydrochloride may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
OUTLINE: This is a phase I, dose-escalation study of nanoparticle albumin-bound rapamycin
followed by a phase II study.
Participants receive ABI-009 intravenously (IV) on days 1 and 8 and pazopanib hydrochloride
orally (PO) daily on days 1-21. Cycles repeat every 21 days until unequivocal clinical
disease progression, unacceptable toxicity, or until in the opinion of the investigator the
patient is no longer benefiting from therapy, or at the patient's discretion.
After completion of study treatment, participants are followed up at 30 days, then every 12
- Patients must have a histologically confirmed diagnosis of non-adipocytic STS that is
either metastatic or locally advanced and for which curative therapy is not available,
surgery is not a recommended option, and pazopanib treatment is indicated.
- Subjects must have one or more measurable target lesions by Response Evaluation
Criteria in Solid Tumors (RECIST) version (v)1.1, assessed via computed tomography
(CT) scan or magnetic resonance imaging (MRI).
- Clinical or radiological progression or failure due to toxicity on at least 1 prior
regimen of systemic treatment for advanced disease. Subjects may not have received
more than 4 prior lines of systemic therapy (no more than 2 prior therapies may be
combination cytotoxic therapies). Neo-adjuvant/adjuvant/maintenance treatments are not
included for this criterion.
- Last dose of prior therapy must have been completed a minimum of 14 days prior to
start of protocol therapy. All ongoing toxicities related to prior therapy must be
resolved or grade 1 (except alopecia).
* NOTE: Toxicities from prior therapy that have resolved with sequalae (e.g.
hypothyroidism) and are asymptomatic or well-controlled are not exclusionary.
- Total bilirubin =< upper limit of normal (ULN) mg/dL (Subjects with known Gilbert's
syndrome and a total bilirubin =< 3 mg/dl are permitted to enroll to phase 2/expansion
phase only with investigator approval).
- Aspartate aminotransferase (AST) =< 2.5 x ULN and alanine aminotransferase (ALT) =<
2.5 x ULN.
- Serum creatinine =<1.5 x ULN (If serum creatinine is > 1.5 mg/dL, calculated
creatinine clearance > 50 mL/min using the Cockcroft-Gault formula may be included).
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
- Platelet count >= 100,000/mm^3 (100 x 10^9/L).
- Hemoglobin >= 9 g/dL.
- Serum triglyceride =< 300 mg/dL.
- Serum cholesterol =< 350 mg/dL.
- Baseline cardiac left ventricular ejection fraction (LVEF) within institutional limits
of normal (by echocardiogram or multigated acquisition [MUGA] study).
- Baseline electrocardiogram with corrected QT (QTc) < 480 millisecond.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Male or non-pregnant and non-breast feeding female:
- Females of child-bearing potential must agree to use highly effective
contraception without interruption from initiation of therapy and while on study
medication and have a negative serum pregnancy test (beta human chorionic
gonadotropin [beta-hCG]) result at screening and agree to ongoing pregnancy
testing during the course of the study, and at the end of study treatment. A
highly effective method of contraception is defined as one that results in a low
failure rate (that is, < 1% per year), when used consistently and correctly, such
as implants, injectables, combined oral contraceptives, some intrauterine
contraceptive devices, sexual abstinence, or a vasectomized partner.
- Male patients must practice abstinence or agree to use a condom during sexual
contact with a pregnant female or a female of childbearing potential while
participating in the study.
- Life expectancy of > 3 months, as determined by the investigator.
- Ability to understand and sign informed consent.
- Willingness and ability to comply with scheduled visits, laboratory tests, and other
- Soft tissue sarcomas with biology or defined treatments for which pazopanib is not
indicated, including adipocytic STS, gastrointestinal stromal tumors (GIST), or
- Previously received an mTOR inhibitor or angiogenesis inhibitor.
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A
subject with controlled and asymptomatic CNS metastases may participate in this study.
As such, the patient must have completed any prior treatment for CNS metastases >= 28
days (including radiotherapy and/or surgery) prior to start of treatment in this study
and should not be receiving chronic corticosteroid therapy for the CNS metastases.
- Subjects with hemoptysis, central nervous system hemorrhage or gastrointestinal
hemorrhage within the last 6 months prior to treatment are excluded due to
pazopanib-associated risk of bleeding.
- Subjects with severe hepatic impairment and active gastrointestinal bleeding.
- Uncontrolled serious medical or psychiatric illness.
- Subjects with a currently active second malignancy other than non-melanoma skin
cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, or
other adequately treated carcinoma-in-situ are ineligible. Subjects are not considered
to have a currently active malignancy if they have completed therapy and are free of
disease for >= 1 year).
- Recent infection requiring systemic anti-infective treatment that was completed =< 14
days prior to enrollment (with the exception of uncomplicated urinary tract infection
or upper respiratory tract infection).
- No clinically significant gastrointestinal abnormalities including malabsorption
syndrome, major resection of the stomach or small bowel that could affect the
absorption of study drug, active peptic ulcer disease, inflammatory bowel disease,
ulcerative colitis, or other gastrointestinal conditions with increased risk of
perforation, history of abdominal fistula, gastrointestinal perforation, or
intra-abdominal abscess within 28 days prior to beginning study treatment.
- Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HbA1c) > 8% despite
- Subjects with unstable coronary artery disease, myocardial infarction, or an arterial
thromboembolic event during preceding 6 months.
- Subjects with history of interstitial lung disease and/or pneumonitis, or pulmonary
- Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving
the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with
narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,
dihydroergotamine, pimozide, quinidine, terfenadine) within the 14 days prior to
receiving the first dose of ABI-009.
- Active hepatitis B or hepatitis C infection.
- Systemic immunosuppression, including human immunodeficiency virus (HIV) positive
status with or without acquired immunodeficiency syndrome (AIDS).
- Subjects with history of intestinal perforations, fistula, hemorrhages and/or
hemoptysis =< 6 months prior to first study treatment.
- Subjects with hypercholesterolemia receiving ongoing treatment with simvastatin.
- Subjects who have had major surgery within 28 days of planned initiation of protocol
therapy, or patients who have/have had wound dehiscence, or other open wounds
(including diabetic or infectious wounds) with active wound complications.
- Subjects with prior history of severe hypersensitivity (grade 3 or higher) to any
known drug excipients, including anaphylaxis to human serum albumin.
- Subjects with uncontrolled hypertension, defined as an average systolic blood pressure
(SBP) >= 140 mmHg or an average diastolic blood pressure (DBP) >= 90 mmHg despite best
supportive care measures.